A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Active, not recruiting · NCT07656727 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 | 2026-09-10 | NCT07656727 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioAge Labs, Inc. | 2 |
17 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Site 100 | Rogers | United States | 1 |
| Site 101 | San Antonio | United States | 1 |
| Site 102 | Miami | United States | 1 |
| Site 103 | Lexington | United States | 1 |
| Site 104 | Port Orange | United States | 1 |
| Site 105 | San Juan | Puerto Rico | 1 |
| Site 106 | Rockville | United States | 1 |
| Site 108 | Chandler | United States | 1 |
| Site 109 | Maitland | United States | 1 |
| Site 110 | Tucson | United States | 1 |
| Site 111 | Hartsdale | United States | 1 |
| Site 112 | Austin | United States | 1 |
| Site 113 | Kansas City | United States | 1 |
| Site 114 | Dallas | United States | 1 |
| Site 115 | Peoria | United States | 1 |
| Site 116 | Las Vegas | United States | 1 |
| Site 117 | Sugar Land | United States | 1 |